SARS-CoV-2-IN-82, identified by its CAS number 924058-34-4, is a small molecule inhibitor designed to target the SARS-CoV-2 virus, which is responsible for COVID-19. This compound is part of a broader class of antiviral agents aimed at disrupting the viral life cycle, particularly by inhibiting key viral proteins essential for replication. The characteristics of SARS-CoV-2-IN-82 include its molecular structure, which is optimized for binding to specific viral targets, potentially enhancing its efficacy against the virus. It is typically evaluated for its potency, selectivity, and safety profile through various biochemical assays and in vivo studies. The compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are also critical for determining its suitability as a therapeutic agent. Research into SARS-CoV-2-IN-82 contributes to the ongoing efforts to develop effective treatments for COVID-19, particularly in the context of emerging variants and the need for novel antiviral strategies.

SARS-CoV-2-IN-82

924058-34-4: SARS-CoV-2-IN-82, identified by its CAS number 924058-34-4, is a small molecule inhibitor designed to target the SARS-CoV-2 virus, which is responsible for COVID-19. This compound is part of a broader class of antiviral agents aimed at disrupting the viral life cycle, particularly by inhibiting key viral proteins essential for replication. The characteristics of SARS-CoV-2-IN-82 include its molecular structure, which is optimized for binding to specific viral targets, potentially enhancing its efficacy against the virus. It is typically evaluated for its potency, selectivity, and safety profile through various biochemical assays and in vivo studies. The compound's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are also critical for determining its suitability as a therapeutic agent. Research into SARS-CoV-2-IN-82 contributes to the ongoing efforts to develop effective treatments for COVID-19, particularly in the context of emerging variants and the need for novel antiviral strategies.

<p>SARS-CoV-2-IN-82 (compound A) acts as an inhibitor of the Programmed-1 ribosomal frameshift (-1 PRF) in SARS-CoV-2 [1].</p>

CAS 924058-34-4

SARS-CoV-2-IN-82

SARS-CoV-2-IN-82

Ref: TM-T87361